


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.


Listing of Claims:

Claim 1 (currently amended): A combination for simultaneous, separate or sequential use which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine of formula I



(I)


or a pharmaceutically acceptable salt thereof and (b) at least one histone deacetylase inhibitor in free form ~~or~~ or in a pharmaceutically acceptable salt form thereof and optionally at least one pharmaceutically acceptable carrier, [.] wherein at least one histone deacetylase inhibitor is selected from the group consisting of sodium butyrate, MS-275, SAHA, aphacidin, depsipeptide, FK 228, trichostatin A, Compound of formula II or a pharmaceutically acceptable



salt thereof

(II)

and Compound of formula III or a pharmaceutically acceptable salt thereof,



(III),

and optionally at least one pharmaceutically acceptable carrier.

Claim 2 (canceled):

Claim 3 (original): The combination according to claim 2 wherein (b) is selected from the group consisting of sodium butyrate, SAHA, Compound of formula II and Compound of formula III.

Claims 4-6 (canceled)

Claim 7 (previously presented): A method of treating a warm-blooded animal having a leukemia comprising administering to the animal a combination according to claim 1 in a quantity which is jointly therapeutically effective against said leukemia and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 8 (previously presented): A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a leukemia of a pharmaceutical combination according to claim 1 and at least one pharmaceutically acceptable carrier.

Claim 9 (previously presented): A commercial package comprising a combination according to claim 1 together with instructions for simultaneous, separate or sequential use thereof in the treatment of a leukemia.

Claim 10 (canceled)